Literature DB >> 2859798

Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease.

H D White, J F Polak, J Wynne, B L Holman, E M Antman, R W Nesto.   

Abstract

The effects of oral nifedipine on left ventricular (LV) diastolic function were assessed in 14 patients with coronary artery disease (CAD) who had symptoms despite therapy with beta-adrenoceptor blocking drugs and nitrates. Rest and exercise gated radionuclide ventriculography was performed before and a mean of 13 days after the addition of oral nifedipine (80 to 120 mg/day) to baseline medication. Ejection fraction did not increase in any patient during exercise. The addition of nifedipine slightly improved the LV ejection fraction response to exercise (control, 49 +/- 8% rest vs 44 +/- 9% exercise; nifedipine, 47 +/- 6% vs 48 +/- 8%). With nifedipine treatment, diastolic function improved, with a decrease in the time to peak filling rate (PFR) at rest (from 174 +/- 34 to 152 +/- 31 ms, p less than 0.005) and an increase in PFR with exercise (from 2.5 +/- 0.6 to 3.4 +/- 0.7 end-diastolic volume/s, p less than 0.0005). Using the ratio of PFR/peak ejection rate as a variable, preferential improvement of diastolic over systolic function occurred during exercise (1.03 +/- 0.29 baseline vs 1.4 +/- 0.43 with nifedipine, p less than 0.01). Duration of exercise increased by a mean of 21% with nifedipine (from 454 +/- 150 to 550 +/- 159 seconds, p less than 0.005); all 14 patients were limited by angina pectoris at baseline, whereas only 5 patients were limited by angina pectoris after nifedipine treatment. This study shows that global LV diastolic function is improved by oral nifedipine treatment both at rest and during exercise in patients on maximally tolerated doses of beta-adrenoreceptor blockers and nitrates, and is associated with improvement of symptoms and exercise tolerances.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859798     DOI: 10.1016/0002-9149(85)90493-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker therapy.

Authors:  W E M Kok; F C Visser; C A Visser
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

Review 3.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

4.  Efficacy of the calcium antagonist isradipine in angina pectoris.

Authors:  J O Parker; M Enjalbert; V Bernstein
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.